CLINICAL TRIALS PROFILE FOR BELUMOSUDIL MESYLATE
✉ Email this page to a colleague
All Clinical Trials for belumosudil mesylate
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT06105554 ↗ | Phase I/II Open Label Study of Belumosudil Mesylate Alone, and in Combination With Dexamethasone, in Patients With Relapsed/Refractory Multiple Myeloma | Recruiting | Sanofi US Services, Inc | Phase 1/Phase 2 | 2024-01-30 | Phase 1 is to find the recommended dose of belumosudil mesylate that can be given to patients with relapsed/refractory MM. Phase 2 is to learn if the dose of belumosudil mesylate found in Phase 1 can help to control the disease. |
NCT06105554 ↗ | Phase I/II Open Label Study of Belumosudil Mesylate Alone, and in Combination With Dexamethasone, in Patients With Relapsed/Refractory Multiple Myeloma | Recruiting | M.D. Anderson Cancer Center | Phase 1/Phase 2 | 2024-01-30 | Phase 1 is to find the recommended dose of belumosudil mesylate that can be given to patients with relapsed/refractory MM. Phase 2 is to learn if the dose of belumosudil mesylate found in Phase 1 can help to control the disease. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for belumosudil mesylate
Condition Name
Clinical Trial Locations for belumosudil mesylate
Trials by Country
Clinical Trial Progress for belumosudil mesylate
Clinical Trial Phase
Clinical Trial Sponsors for belumosudil mesylate
Sponsor Name